HC Wainwright Has Positive Estimate for Chimerix Q4 Earnings

Chimerix, Inc. (NASDAQ:CMRX) – Investment analysts at HC Wainwright upped their Q4 2024 earnings per share estimates for shares of Chimerix in a research report issued to clients and investors on Wednesday, December 11th. HC Wainwright analyst E. White now forecasts that the biopharmaceutical company will post earnings of ($0.24) per share for the quarter, up from their prior forecast of ($0.25). HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Chimerix’s current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Chimerix’s Q1 2025 earnings at ($0.29) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($0.99) EPS.

Several other equities research analysts also recently commented on the stock. Wedbush reaffirmed an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a report on Tuesday, December 10th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Wednesday, August 21st.

Chimerix Trading Up 0.3 %

NASDAQ:CMRX opened at $2.95 on Friday. The firm’s 50 day moving average is $1.07 and its 200 day moving average is $0.96. Chimerix has a 12 month low of $0.75 and a 12 month high of $3.39. The stock has a market capitalization of $265.32 million, a PE ratio of -3.14 and a beta of 1.02.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC increased its position in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 69,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Chimerix in the second quarter worth $137,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.